Vyome Holdings (HIND) Income from Continuing Operations (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Income from Continuing Operations of 1274359.0 for Q1 2026, down 186.46% year-over-year from 1474000.0 in Q1 2025, and up 7.98% quarter-over-quarter from 1384815.0 in Q4 2025.
Vyome Holdings (HIND) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Vyome Holdings' Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 1274359.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 186.46% year-over-year to 1274359.0; the TTM figure through Mar 2026 stood at 13889088.0 (down 301.07% YoY), while the FY2025 annual figure was 85646745.0, down 1101.22% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 1274359.0, up from 1384815.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1474000.0 in Q1 2025, with the low at 16834000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 2630000.0 (2025), against an average of 4559475.76.
- Peak annual rise in Income from Continuing Operations reached 167.21% in 2025, while the deepest fall reached 443.95% in 2025.
- Vyome Holdings' Income from Continuing Operations stood at 16834000.0 in 2022, then surged by 89.91% to 1698000.0 in 2023, then slipped by 3.71% to 1761000.0 in 2024, then grew by 21.36% to 1384815.0 in 2025, then climbed by 7.98% to 1274359.0 in 2026.
- Business Quant data shows HIND's Income from Continuing Operations at 1274359.0 in Q1 2026, 1384815.0 in Q4 2025, and 8599914.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | -865,891.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.01 Mn |
| Mar 31, 2026 | -1.27 Mn |
| Dec 31, 2025 | -1.38 Mn |
| Sep 30, 2025 | -8.60 Mn |
| Jun 30, 2025 | -2.63 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Dec 31, 2024 | -1.76 Mn |
| Sep 30, 2024 | -1.58 Mn |
| Jun 30, 2024 | -1.60 Mn |
| Mar 31, 2024 | -2.19 Mn |
| Dec 31, 2023 | -1.70 Mn |
| Sep 30, 2023 | -3.53 Mn |
| Jun 30, 2023 | -3.49 Mn |
| Mar 31, 2023 | -2.66 Mn |
| Dec 31, 2022 | -16.83 Mn |
| Sep 30, 2022 | -12.19 Mn |
| Jun 30, 2022 | -9.44 Mn |
| Mar 31, 2022 | -8.12 Mn |
| Dec 31, 2021 | -37.53 Mn |
| Sep 30, 2021 | -17.13 Mn |